论文信息 - Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023 - 字舞流文

Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023

J. Schellens | H. Rosing | J. Beijnen | M. Piccart-Gebhart | A. Awada | A. Huitema | V. Diéras | M. Mergui-Roelvink | S. Marréaud | C. Tourneau | A. Govaerts | B. M. Kerklaan | Anne-Sophie Govaerts